Articles
| Open Access |
https://doi.org/10.55640/
GLP-1 RECEPTOR AGONISTS BEYOND OBESITY: EXPANDING HORIZONS IN CARDIOMETABOLIC, RENAL, AND NEUROLOGICAL DISEASE
Noor Alam , Assistant Professor Department of Folk Medicine and Pharmacology Fergana Medical Institute of Public Health, Yangi Turon- 2A, Ferghana-150100, UzbekistanAbstract
Glucagon-like peptide-1 (GLP-1) receptor agonists were initially created to reduce blood glucose in type 2 diabetes (T2D). In the last ten years, there has been clear evidence of their effectiveness beyond glucose-lowering and weight loss. This review consolidates the emerging evidence on the pleiotropic actions of GLP-1 receptor agonists in cardiovascular, renal, liver, brain, and inflammation. Pioneering cardiovascular outcomes studies (LEADER, SUSTAIN-6, REWIND, and SELECT) have shown marked improvement in major adverse cardiovascular events (MACE), hospitalizations for heart failure, and cardiovascular death. Growing evidence suggests renoprotective effects beyond glucose lowering, and preclinical and early clinical data show promise in non-alcoholic steatohepatitis (NASH), neurodegenerative diseases, and addiction. These results suggest that GLP-1 receptor agonists are a game-changing drug class with a wide range of potential applications beyond metabolic disease.
Keywords
GLP-1 receptor agonists; semaglutide; liraglutide; cardiovascular outcomes; chronic kidney disease; NASH; neurodegeneration; heart failure
References
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165.
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786.
Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30.
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–662.
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7(10):776–785.
Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Lancet Diabetes Endocrinol. 2018;6(8):605–617.
Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease. Neuropharmacology. 2016;110:229–244.
Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311–322.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394(10193):121–130.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1063–1075.
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–3639.
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109–121.
KDIGO 2024 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314.
Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN). Lancet. 2016;387(10019):679–690.
Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis (ESSENCE). N Engl J Med. 2024;390(13):1180–1192.
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease. Endocr Pract. 2022;28(5):528–562.
Bhatt DL, Lincoff AM, Gibson CM, et al. Icosapentaenoic acid and cardiovascular outcomes. N Engl J Med. 2019;380(1):11–22. [Note: Nandipati S, et al. GLP-1 agonists and Parkinson's disease risk: a population-based study. JAMA Neurol. 2023;80(4):398–406.]
Meissner WG, Remy P, Giordana C, et al. Trial of lixisenatide in early Parkinson's disease. N Engl J Med. 2024;390(13):1176–1178.
Holst JJ, Vilsbøll T. Combining GLP-1 receptor agonists with insulin. Diabetes Obes Metab. 2013;15(8):701–710. [Note: Cummings J. Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin Transl Sci. 2018;11(2):147–151.]
Nørgaard CH, Søndergaard Toft A, Fink-Jensen A, et al. Glucagon-like peptide-1 receptor agonists and risk of dementia in persons with type 2 diabetes. Alzheimers Dement. 2022;18(12):2569–2581.
Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022;179(4):625–641.
Becker WC, Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020;173(1):59–60. [Note: Simó R, et al. GLP-1 receptor agonists and alcohol use: a population-based cohort study. Lancet Reg Health Eur. 2024;38:100840.]
Jensterle M, Sebestjen M, Janez A, et al. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;159(4):399–406. [Note: Silva CA, et al. GLP-1 RAs in PCOS. Curr Pharm Des. 2023;29(9):728–738.]
Connelly KA, Zhang Y, Desjardins JF, et al. GLP-1 receptor agonism in COVID-19: potential mechanisms and clinical implications. Cardiovasc Res. 2022;118(11):2436–2446.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
FDA Drug Safety Communication: FDA evaluating the risk of non-arteritic anterior ischemic optic neuropathy (NAION) with GLP-1 agonists. US FDA; 2024.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity (TRIUMPH-1). N Engl J Med. 2023;389(6):514–526.
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.